| __timestamp | Amphastar Pharmaceuticals, Inc. | argenx SE |
|---|---|---|
| Wednesday, January 1, 2014 | 40373000 | 4241601.57 |
| Thursday, January 1, 2015 | 46974000 | 5392385.38 |
| Friday, January 1, 2016 | 47298000 | 7370036.73 |
| Sunday, January 1, 2017 | 50918000 | 14970357 |
| Monday, January 1, 2018 | 58044000 | 31413266 |
| Tuesday, January 1, 2019 | 63109000 | 72279461 |
| Wednesday, January 1, 2020 | 65157000 | 183907682 |
| Friday, January 1, 2021 | 68920000 | 307644000 |
| Saturday, January 1, 2022 | 66592000 | 472132000 |
| Sunday, January 1, 2023 | 80393000 | 709539000 |
In pursuit of knowledge
In the competitive landscape of the pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, from 2014 to 2023, argenx SE and Amphastar Pharmaceuticals, Inc. have shown contrasting trends in their SG&A expenses. Amphastar's expenses have grown steadily, increasing by approximately 99% from 2014 to 2023. In contrast, argenx SE has experienced a dramatic surge, with expenses skyrocketing by over 16,600% during the same period. This stark difference highlights argenx SE's aggressive expansion and investment in administrative capabilities. As of 2023, argenx SE's SG&A expenses are nearly nine times higher than Amphastar's, reflecting its strategic focus on scaling operations. These insights provide a window into the financial strategies of these two pharmaceutical giants, offering valuable lessons for investors and industry analysts alike.
Merck & Co., Inc. vs Amphastar Pharmaceuticals, Inc.: SG&A Expense Trends
Gilead Sciences, Inc. vs Amphastar Pharmaceuticals, Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: argenx SE vs Biogen Inc.
Cost Management Insights: SG&A Expenses for argenx SE and Blueprint Medicines Corporation
Selling, General, and Administrative Costs: argenx SE vs Verona Pharma plc
Comparing SG&A Expenses: argenx SE vs Veracyte, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for argenx SE and Soleno Therapeutics, Inc.
Intra-Cellular Therapies, Inc. or Amphastar Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
TG Therapeutics, Inc. or Amphastar Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of CRISPR Therapeutics AG and Amphastar Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Merus N.V. or Amphastar Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Amphastar Pharmaceuticals, Inc. and Galapagos NV